Kearney has released a detailing how glucagon-like peptide-1 agonists (GLP-1s) are potentially putting profits across eight therapeutic areas at risk.
Some key findings of the report include:
- An estimated 60% reduction in procedure profits is predicted by 2029.
- Coronary artery bypass grafting profits are estimated to decrease by 74%.
- Considering the psychological effects of GLP-1 treatments on body image, Kearney predicts profits from neuromodulator injection procedures (like Botox) could increase by 34%.
- Using projected Medicare data, the study determines how provider systems could feel the effects of GLP-1s.
More details and figures can be found in the report, Fight for survival: how GLP-1s have created an existential threat to US providers.
